New CAR-T therapy targets tough lymphoma in early trial
NCT ID NCT05784441
First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. The main goals are to find a safe dose and see if the therapy can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JNJ-90009530 (a CAR-T cell therapy targeting CD20)
- What this could lead to
- If successful, this could provide a new treatment option for patients with hard-to-treat lymphoma who have run out of standard therapies.
- What could go wrong
- This is a very early (phase 1b) and small (21 participants) study focused on safety and dosing. It may not lead to a widely available treatment, and CAR-T therapies carry risks like severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
21 people
The number who actually took part.
- Started
-
Nov 2023
- Expected to finish
-
Jan 2040
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * All participants must have relapsed or refractory disease for each histologic subtype * Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Participants must have \>= 2 lines of systemic therapy or \>=1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). Participants also must have had exposure to an anthracycline and an anti-CD20 targeted agent * Follicular lymphoma Grade 1-3a and Marginal Zone Lymphoma: Participants must have \>=2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody * Tumor must be cluster of differentiation (CD) 20 positive * Measurable disease as defined by Lugano 2014 classification * Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 Key Exclusion Criteria * Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL) * Prior allogeneic Hematopoietic stem cell transplantation (HSCT) * Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion * Uncontrolled active infections * History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis \[DVT\]) * History of stroke, unstable angina, myocardial infarction, congestive heart failure ( New York Heart Association \[NYHA\] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening * History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder * Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system * Active central nervous system (CNS) involvement by malignancy * Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory B cell non-Hodgkin lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Monash Medical Centre
Clayton, 3168, Australia
-
Royal Brisbane and Women's Hospital
Herston, 4029, Australia
-
Royal Prince Alfred Hospital
Camperdown, 2050, Australia
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
-
Sheba Medical Center
Ramat Gan, 5266202, Israel
-
University College London Hospitals
London, NW1 2BU, United Kingdom
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Iowa Hospital
Iowa City, Iowa, 52242, United States
-
University of Kentucky
Lexington, Kentucky, 40506, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Westmead Hospital
Westmead, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
- New pill targets Hard-to-Treat lymphoma in early human test
- New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
- New hope for tough cancers: experimental drug LP-284 enters human testing
- Engineered immune cells take on childhood blood cancers in early trial
- New combo aims to tackle tough lymphomas